| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Howard Hughes Medical Institute, Departments of Cell Biology [S-H. C., S. L. C. W.], Otorhinolaryngology-Head and Neck Surgery [B. W. O.], and Pathology [M. R. S.], Baylor College of Medicine, Houston, Texas 77030
Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir administration was used to treat human head and neck cancer in nude mice. Tumors were generated by transcutaneous needle injection of 6 x 106 human squamous carcinoma cells into the floor of the mouth. After 14 days, 1010 particles of a replication-defective recombinant adenovirus containing the herpes simplex virus thymidine kinase gene (ADV/RSV-tk) were injected directly into the tumors. The mice subsequently received ganciclovir injections for six consecutive days and were sacrificed at 21 days post tumor cell implantation. Clinical response to the treatment was assessed by computer-imaged morphometric analysis of cross sectional area of nonnecrotic tumor and mitotic activity, which were used for the calculation of a tumor index. The median tumor index value of the treatment group was 280- to 2400-fold smaller than controls which did not receive the therapeutic gene (P < 0.001–0.016), and three-quarters of the treatment group had tumor index values that were indicative of near total tumor regression. Survival studies show that 50% of the ADV/RSV-tk-treated mice are free of tumor at 160 days post adenovirus injection, while all controls died or required sacrifice within 43 days. These results demonstrate that clinically effective in vivo treatment of human squamous cell cancer can be achieved using adenovirus-mediated gene therapy.
1 S.L.C.W. is an investigator and S.H.C. is an associate of the Howard Hughes Medical Institute.
2 To whom requests for reprints should be addressed, at Department of Cell Biology, Baylor College of Medicine, One Baylor Plaza Room T721, Houston, TX 77030.
Received 8/17/94. Accepted 12/28/94.
This article has been cited by other articles:
|
|
 |
|
  P. D. Boucher, M. M. Im, S. O. Freytag, and D. S. Shewach A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res., March 15, 2006; 66(6): 3230 - 3237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takeda, H. Inaba, M. Yamazaki, S. Kyo, T. Miyamoto, S. Suzuki, T. Ehara, T. Kakizawa, M. Hara, L. J. DeGroot, et al. Tumor-Specific Gene Therapy for Undifferentiated Thyroid Carcinoma Utilizing the Telomerase Reverse Transcriptase Promoter J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3531 - 3538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kojima, M. Iida, H. Miyazaki, T. Koga, H. Moriyama, and Y. Manome Enhancement of Cytarabine Sensitivity in Squamous Cell Carcinoma Cell Line Transfected With Deoxycytidine Kinase Arch Otolaryngol Head Neck Surg, June 1, 2002; 128(6): 708 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hasenburg, D.-C. Fischer, X.-W. Tong, A. Rojas-Martinez, R. H. Kaufman, I. Ramzy, P. Kohlberger, M. Orlowska-Volk, E. Aguilar-Cordova, and D. G. Kieback Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins {alpha}v{beta}3 and {alpha}v{beta}5 Reproductive Sciences, May 1, 2002; 9(3): 174 - 180. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Minemura, T. Takeda, K. Minemura, T. Nagasawa, R. Zhang, R. Leopardi, and L. J. DeGroot Cell-Specific Induction of Sensitivity to Ganciclovir in Medullary Thyroid Carcinoma Cells by Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase Endocrinology, May 1, 2000; 141(5): 1814 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Boucher, L. J. Ostruszka, and D. S. Shewach Synergistic Enhancement of Herpes Simplex Virus Thymidine Kinase/Ganciclovir-mediated Cytotoxicity by Hydroxyurea Cancer Res., March 1, 2000; 60(6): 1631 - 1636. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Li, L. Duan, P. Freimuth, and B. W. O'Malley Jr. Variability of Adenovirus Receptor Density Influences Gene Transfer Efficiency and Therapeutic Response in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4175 - 4181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kasono, J. L. Blackwell, J. T. Douglas, I. Dmitriev, T. V. Strong, P. Reynolds, D. A. Kropf, W. R. Carroll, G. E. Peters, R. P. Bucy, et al. Selective Gene Delivery to Head and Neck Cancer Cells via an Integrin Targeted Adenoviral Vector Clin. Cancer Res., September 1, 1999; 5(9): 2571 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Blackwell, C. R. Miller, J. T. Douglas, H. Li, P. N. Reynolds, W. R. Carroll, G. E. Peters, T. V. Strong, and D. T. Curiel Retargeting to EGFR Enhances Adenovirus Infection Efficiency of Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, August 1, 1999; 125(8): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. O’Malley Jr., D. A. Sewell, D. Li, K.-i. Kosai, S.-H. Chen, S. L.C. Woo, and L. Duan The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer Mol. Endocrinol., June 1, 1997; 11(6): 667 - 673. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
